Abstract | BACKGROUND:
Reactive oxygen species (ROS) contribute to adult tumorigenesis; however, their roles in pediatric solid tumors are unknown. Here, we sought to define the steady-state ROS levels in neuroblastoma and to examine whether aggressive cellular behavior, which may predict treatment failure, is regulated by ROS. METHODS:
Neuroblastoma sections were assessed for 4-hydroxynonenal (4-HNE), a marker of intracellular lipid peroxidation and a byproduct of increased levels of ROS. Human neuroblastoma cell lines, MYCN-amplified BE(2)-C and MYCN-nonamplified SK-N-SH, were examined in our study. Superoxide and hydroperoxide oxidation products were detected by staining for dihydroethidium (DHE) and 5, 6-carboxy-2', 7'-dichlorodihydrofluorescein diacetate (CDCFH2), using the oxidation-insensitive analog CDCF as a negative control. Cells were treated with N-acetylcysteine (NAC; 10 mmol/L) daily for 5 days and analyzed. RESULTS: CONCLUSION: We report a novel observation that shifting the redox balance toward greater ROS levels results in a more aggressive neuroblastoma phenotype. Our data suggest that ROS play a critical role in refractory neuroblastoma.
|
Authors | Yueming Zhu, Pritha Paul, Sora Lee, Brian T Craig, Eric J Rellinger, Jingbo Qiao, David R Gius, Dai H Chung |
Journal | Surgery
(Surgery)
Vol. 158
Issue 3
Pg. 827-36
(Sep 2015)
ISSN: 1532-7361 [Electronic] United States |
PMID | 26088922
(Publication Type: Evaluation Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- Antioxidants
- Biomarkers, Tumor
- Reactive Oxygen Species
- Acetylcysteine
|
Topics |
- Acetylcysteine
(pharmacology)
- Antioxidants
(pharmacology)
- Biomarkers, Tumor
(metabolism)
- Blotting, Western
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Humans
- Immunohistochemistry
- Neuroblastoma
(metabolism)
- Reactive Oxygen Species
(antagonists & inhibitors, metabolism)
|